视觉评估结合统计参数映射分析在儿童癫痫患者中的葡萄糖代谢特征
本研究纳入100例儿童癫痫患者和15例年龄匹配对照,采用18F-FDG PET/CT显像,通过视觉评估结合统计参数映射(SPM)分析葡萄糖代谢特征。结果显示,视觉评估联合SPM分析较单纯视觉评估能检出更多葡萄糖代谢异常患者;在代谢异常患者中,|AI|与癫痫发作频率显著正相关(P < 0.01),与末次发作后时间显著负相关(P < 0.01)。作者认为|AI|可能用于评估临床严重程度和病情进展,推迟扫描至更接近临床发作时可能提升PET的临床价值。
要点
- 视觉评估联合SPM分析较单纯视觉评估可检出更多儿童癫痫患者存在葡萄糖代谢异常。
- 在代谢异常患者中,|AI|与发作频率正相关(P < 0.01),与末次发作后时间负相关(P < 0.01)。
- 在低代谢(P < 0.01)和高代谢(P = 0.209)患者中,耐药者|AI|均高于发作缓解者。
核心结论
- 18F-FDG PET显像结合视觉评估与SPM分析可提供非手术癫痫患者的脑葡萄糖代谢特征。
- |AI|可能用于评估这些患者的临床严重程度和病情进展。
- 癫痫无发作持续时间较长的患者,PET上代谢异常可能更轻微或不存在。
- 将扫描时间安排得更接近临床发作,可能提升PET的临床价值。
研究设计与样本
- 纳入100例接受18F-FDG PET/CT、MRI和脑电图检查的儿童癫痫患者,另纳入15例年龄匹配对照。
- 采用视觉评估结合统计参数映射(SPM)分析18F-FDG PET图像。
- 对存在局部葡萄糖代谢异常的患者计算绝对不对称指数(|AI|)。
主要发现
- 视觉评估联合SPM分析较单纯视觉评估检出更多葡萄糖代谢异常患者。
- 在代谢异常患者中,|AI|与癫痫发作频率显著正相关(P < 0.01),与末次发作后时间显著负相关(P < 0.01)。
- 在低代谢患者(P = 0.001)和高代谢患者(P = 0.005)中,对|AI|唯一显著的贡献变量均为末次发作后时间。
- 在低代谢患者中(P < 0.01)和高代谢患者中(P = 0.209),耐药者|AI|值均高于发作缓解者。
- 在1年随访PET研究中,临床改善患者较持续或进展患者的|AI|(%)有显著变化(P < 0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PET with 18F-FDG has been used for presurgical localization of epileptogenic foci; however, in nonsurgical patients, the correlation between cerebral glucose metabolism and clinical severity has not been fully understood. The aim of this study was to evaluate the glucose metabolic profile using 18F-FDG PET/CT imaging in patients with epilepsy. Methods: One hundred pediatric epilepsy patients who underwent 18F-FDG PET/CT, MRI, and electroencephalography examinations were included. Fifteen age-matched controls were also included. 18F-FDG PET images were analyzed by visual assessment combined with statistical parametric mapping (SPM) analysis. The absolute asymmetry index (|AI|) was calculated in patients with regional abnormal glucose metabolism. Results: Visual assessment combined with SPM analysis of 18F-FDG PET images detected more patients with abnormal glucose metabolism than visual assessment only. The |AI| significantly positively correlated with seizure frequency (P < 0.01) but negatively correlated with the time since last seizure (P < 0.01) in patients with abnormal glucose metabolism. The only significant contributing variable to the |AI| was the time since last seizure, in patients both with hypometabolism (P = 0.001) and with hypermetabolism (P = 0.005). For patients with either hypometabolism (P < 0.01) or hypermetabolism (P = 0.209), higher |AI| values were found in those with drug resistance than with seizure remission. In the post-1-y follow-up PET studies, a significant change of |AI| (%) was found in patients with clinical improvement compared with those with persistence or progression (P < 0.01). Conclusion:18F-FDG PET imaging with visual assessment combined with SPM analysis could provide cerebral glucose metabolic profiles in nonsurgical epilepsy patients. |AI| might be used for evaluation of clinical severity and progress in these patients. Patients with a prolonged period of seizure freedom may have more subtle (or no) metabolic abnormalities on PET. The clinical value of PET might be enhanced by timing the scan closer to clinical seizures.
引用
- Zhu Y, Feng J, Wu S, et al. Glucose Metabolic Profile by Visual Assessment Combined with Statistical Parametric Mapping Analysis in Pediatric Patients with Epilepsy. J Nucl Med. 2017. PMID: 28104740. doi:10.2967/jnumed.116.187492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。